Jeffrey Raub, MD
Allergy & Immunology · Cincinnati, OHNPI 1871520551
Payments from drug & device makers
Across 701 payments — averaging $20.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- GSK$2K
- Sanofi$2K
- Regeneron Healthcare Solutions, Inc.$803
- Amgen$672
- Blueprint Medicines Corporation$607
- plus $5K from 31 others
What the payments were for
- Consulting fees$520%
- Food & beverage$14,18298%
- Education$2252%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 107 | $3,100 |
| GSK | 169 | $2,436 |
| Sanofi | 95 | $2,062 |
| Regeneron Healthcare Solutions, Inc. | 35 | $803 |
| Amgen | 38 | $672 |
| Blueprint Medicines Corporation | 10 | $607 |
| Grifols USA, LLC | 30 | $536 |
| Novartis | 24 | $420 |
| Genentech USA, Inc. | 17 | $397 |
| Octapharma USA, Inc. | 21 | $395 |
| Pfizer | 20 | $379 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $353 |
| Kaleo, Inc. | 18 | $343 |
| CSL Behring | 17 | $330 |
| Boehringer Ingelheim | 13 | $193 |
| AbbVie | 5 | $184 |
| Optinose US, Inc. | 8 | $156 |
| Covis Pharma GmbH | 9 | $149 |
| Sanofi-aventis U.S. LLC | 2 | $149 |
| ADMA Biomanufacturing LLC | 8 | $124 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $71 |
| Lilly USA, LLC | 3 | $70 |
| Alk-abello, Inc | 4 | $67 |
| Mylan Specialty L.p. | 4 | $65 |
| GC Biopharma USA, Inc. | 3 | $60 |
| Hospira, Inc. | 3 | $59 |
| Teva Pharmaceuticals USA, Inc. | 4 | $47 |
| Biocryst US Sales Co., LLC | 3 | $46 |
| Nabriva Therapeutics, PLC | 2 | $35 |
| Azurity Pharmaceuticals, Inc. | 2 | $33 |
| Ionis Pharmaceuticals, Inc. | 1 | $25 |
| Aimmune Therapeutics, Inc. | 1 | $22 |
| Biocryst Pharmaceuticals, Inc. | 1 | $15 |
| Merck | 1 | $15 |
| Viatris Specialty LLC | 1 | $14 |
| Pharming Healthcare, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,459 in reported general payments places this provider in the 70th percentile of 128 allergy & immunology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 15 | $77,624 |
| Dupixent PenDupilumab | 18 | $65,730 |
| Dupixent SyringeDupilumab | 14 | $54,230 |
| XolairOmalizumab | 16 | $43,454 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $28,703 |
| Breo ElliptaFluticasone/Vilanterol | 46 | $23,722 |
| Epinephrine | 58 | $11,155 |
| Arnuity ElliptaFluticasone Furoate | 29 | $9,077 |
| Spiriva RespimatTiotropium Bromide | 13 | $8,497 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $6,450 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $4,632 |
| Fluticasone Propionate HfaFluticasone Propionate | 15 | $3,626 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 135 | $3,478 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 37 | $3,474 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 20 | $2,294 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCGamunex-C | $536 | $77,62415 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $2,436 | $61,502112 claims |
| Boehringer IngelheimSpiriva Respimat | $193 | $8,49713 claims |
| AstraZenecaSymbicort | $3,100 | $4,63211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 128 allergy & immunology providers in Ohio.
Other allergy & immunology in Cincinnati
- Jonathan BernsteinCincinnati$4.5M
- David BernsteinCincinnati$2.7M
- Justin GreiweCincinnati$1M
- Sheharyar DurraniCincinnati$953K
- Juan AboniaCincinnati$515K
- Gordon MyersCincinnati$346K
- Joshua BernsteinCincinnati$18K
- David TapkeCincinnati$17K
- John SeyerleCincinnati$8K
- Heather HartmanCincinnati$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.